Author

A. Mumford

Observed name: A Mumford

OpenAlex ID: A5066803723

Puk8 the Economic Impact and Variability of Managing Distral Renal Tubular Acidosis (drta) in the Uk Healthcare Setting

2019 · A. Mumford, J. Mumford, et al. · Value in Health · 3

PDF

POSB96 Economic Model for a Gene Therapy in an Ultra-Rare Disease: Expert Validation of Approach and Assumptions

2022 · L Sopeña, C Simons, et al. · Value in Health · 2

PDF

HTA117 A Comparison of Health Technology Appraisal (HTA) Timelines and Requirements for Orphan Technologies in 10 European Countries

2023 · A. Mumford, G. Roberts, et al. · Value in Health · 1

PDF

PBI18 The Global EARLY Access Programme Landscape and Its Application to Cell and GENE Therapies

2021 · W. Irvin, L. Sopena, et al. · Value in Health · 1

HTA165 A Comparative Analysis of Reimbursement Outcomes for Orphan Drugs Between EU and Non-EU Countries

2024 · SJ Lyttle, H Lewis, et al. · Value in Health

PDF

HTA5 A Review and Evaluation of Reimbursement Outcomes for Non-Orphan and Orphan Drugs in Ireland in 2023

2024 · M Greenwood, SJ Lyttle, et al. · Value in Health

EE202 Conceptualization and Validation of a Health Economic Model for Osteogenesis Imperfecta

2024 · T Edmonds, O Darlington, et al. · Value in Health

PDF

PCR92 The Experience and Utilization of Patient Reported Outcomes (PROs) in Leber’s Hereditary Optic Neuropathy (LHON): A Targeted Literature Review

2023 · A. Mumford, J. Mumford, et al. · Value in Health

PDF

HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis

2023 · A. Mumford, O. Darlington, et al. · Value in Health

PDF

HTA92 A Review and Evaluation of Successfully Reimbursed Orphan and Non-Orphan Drugs in Ireland

2023 · S.J. Lyttle, G. Roberts, et al. · Value in Health

PDF

HTA66 Modified Delphi Research to Seek Consensus on dRTA Disease Model, Treatment, and Management

2023 · A. Mumford, S. Coyle, et al. · Value in Health

HTA76 Increased Legal Certainty Surrounding Medicine Discounting May Increase Switzerland’s Attractiveness As an Early Launch Country

2023 · A. Mumford, D. Ringger · Value in Health

PDF

HPR30 Review of Indication-Based Pricing Practice in Switzerland

2023 · D. Ringger, O. Darlington, et al. · Value in Health

PDF

HPR96 A Comparative Analysis of the Relationship between Orphan Drug Status and Reimbursement Status in Ireland, Sweden, France, and Canada in 2022

2023 · S.J. Lyttle, M. Greenwood, et al. · Value in Health

HPR54 A Review and Evaluation of the UK’s Innovative Licensing and Access Pathway

2023 · D. Ringger, A. Shaw, et al. · Value in Health

PDF

PBI45 Reimbursement Pathways and Associated Timelines in European GENE Therapies

2020 · L. Sopena, A. Mumford, et al. · Value in Health

PDF

PRS20 A Multinational Assessment of Direct and Indirect Costs from a Survey of Patients with Idiopathic Pulmonary Fibrosis (IPF)

2020 · G. Coteur, A. Mumford, et al. · Value in Health

PCN215 Virtual Modified Delphi Research into Current and Future Management Approaches of Multiple Myeloma in Sweden

2020 · G. Roberts, J. Mumford, et al. · Value in Health

PDF

Pns124 Insight in the Hta Process, the Value of Using Modified Delphi

2020 · S. Coyle, A. Mumford, et al. · Value in Health

PDF

Pns127 Negative Reimbursement Decisions and a Review of Methods to Drive to Positive Reimbursed Status

2020 · A. Mumford, B. English, et al. · Value in Health

Prs35 - the Economic Impact and Variability of Managing Non-tuberculous Mycobacterial Lung Disease in the Uk Healthcare Setting

2018 · A. Mumford, J. Mumford, et al. · Value in Health

Works count: 21

Citation count: 7

H-index: 2

I10-index: